Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H22FN7O |
| Molecular Weight | 395.4334 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1N=CN=C1COC2=NN3C(C=C2C(C)(C)C)=NN=C3C4=CC=CC=C4F
InChI
InChIKey=QKIWQBLNTSQOLY-UHFFFAOYSA-N
InChI=1S/C20H22FN7O/c1-5-27-17(22-12-23-27)11-29-19-14(20(2,3)4)10-16-24-25-18(28(16)26-19)13-8-6-7-9-15(13)21/h6-10,12H,5,11H2,1-4H3
| Molecular Formula | C20H22FN7O |
| Molecular Weight | 395.4334 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
MK 0777 is a selective GABAA α2/3 receptor partial agonist, for potential use in the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder. MK-0777 is functionally selective for the α2 and α3 subunits, with virtually no activity for the α1 and α5 subunits. Therefore, MK-0777 cause less sedation, interact less with alcohol, and exhibit less abuse potential and physical dependence than benzodiazepines. Unfortunately, in clinical trials, MK-0777 has little benefit for cognitive impairments in people with schizophrenia and anxiety disorder.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. | 2006 Jan |
|
| Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers. | 2006 Jun |
|
| Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. | 2007 Jun |
|
| Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. | 2008 Jan |
|
| Novel discriminative stimulus effects of TPA023B, subtype-selective gamma-aminobutyric-acid(A)/benzodiazepine modulator: comparisons with zolpidem, lorazepam, and TPA023. | 2008 Jul |
|
| In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist. | 2008 Jul 15 |
|
| Pharmacological Properties of DOV 315,090, an ocinaplon metabolite. | 2008 Jun 13 |
|
| GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer. | 2008 Spring |
|
| Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. | 2009 |
|
| A novel operant conflict procedure using incrementing shock intensities to assess the anxiolytic and anxiogenic effects of drugs. | 2009 May |
|
| GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. | 2010 |
|
| Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes. | 2010 Jan |
|
| Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. | 2010 Jan |
|
| Reversal of ketamine-induced working memory impairments by the GABAAalpha2/3 agonist TPA023. | 2010 May 15 |
|
| A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. | 2011 Mar 1 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:30:51 GMT 2023
by
admin
on
Fri Dec 15 15:30:51 GMT 2023
|
| Record UNII |
1FI3KTC550
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
TPA-023
Created by
admin on Fri Dec 15 15:30:52 GMT 2023 , Edited by admin on Fri Dec 15 15:30:52 GMT 2023
|
PRIMARY | |||
|
9908684
Created by
admin on Fri Dec 15 15:30:52 GMT 2023 , Edited by admin on Fri Dec 15 15:30:52 GMT 2023
|
PRIMARY | |||
|
DB12238
Created by
admin on Fri Dec 15 15:30:52 GMT 2023 , Edited by admin on Fri Dec 15 15:30:52 GMT 2023
|
PRIMARY | |||
|
252977-51-8
Created by
admin on Fri Dec 15 15:30:52 GMT 2023 , Edited by admin on Fri Dec 15 15:30:52 GMT 2023
|
PRIMARY | |||
|
DTXSID10179938
Created by
admin on Fri Dec 15 15:30:52 GMT 2023 , Edited by admin on Fri Dec 15 15:30:52 GMT 2023
|
PRIMARY | |||
|
1FI3KTC550
Created by
admin on Fri Dec 15 15:30:52 GMT 2023 , Edited by admin on Fri Dec 15 15:30:52 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
METABOLIC ENZYME -> SUBSTRATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Tmax | PHARMACOKINETIC |
|
SINGLE DOSE |
|
||
| Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||